Feb 19 Kidney Cancer

Notizia

CRISPR treatment delivers benefits in mice


The researchers from Duke University along with drugmaker Sarepta Therapeutics published a report stating that a single change in the genetic system of Duchenne muscular dystrophy (DMD) affected mice, using CRISPR gene editing tool resulted in increasing their life span by one year. No toxic immune responses were exhibited to Cas9 enzyme used for gene editing.

A step ahead in treating metastatic Kidney Cancer

Drug makers Merck & Co. and Pfizer conducted trials giving thumbs up to pair immunotherapy with a type of targeted drug to treat metastatic Kidney Cancer. In trials, patients who received Merck’s Keytruda and Pfizer’s Bavencio together showed increased chances of survival as compared to those given only Sutent.

University of Louisville develops a drug to target tumors


Researchers at University of Louisville have developed a drug SA-4-1BBL, which when used in concurrence with adaptive T-cells can largely shield from tumors. The novel drug activates CD4+ T cells and Natural Killer cells which have the power to destroy the cancer causing cells in the body even before they get settled.

Bayer and Orion develop a therapy to beat Prostate Cancer


Drug makers Bayer and Orion are jointly developing a therapy to enhance metastasis-free survival. Trials were conducted, which revealed that when Darolutamide added with Androgen Deprivation Therapy (ADT), showed 59 percent decline in the probability of deaths caused than in Placebo with ADT in the patients affected by Prostate Cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.